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Abstract
There exists a strong clinical need for a more capable and robust method to achieve bone
augmentation, and a system with fine-tuned delivery of demineralized bone matrix (DBM) has
potential to meet that need. As such, the objective of the present study was to investigate a
synthetic biodegradable hydrogel for the delivery of DBM for bone augmentation in a rat model.
Oligo(poly(ethylene glycol) fumarate) (OPF) constructs were designed and fabricated by varying
the content of rat-derived DBM particles (either 1:3, 1:1, or 3:1 DBM:OPF weight ratio on a dry
basis) and using two DBM particle size ranges (50–150 or 150–250 μm). The physical properties
of the constructs and the bioactivity of the DBM were evaluated. Select formulations (1:1 and 3:1
with 50–150 μm DBM) were evaluated in vivo compared to an empty control to investigate the
effect of DBM dose and construct properties on bone augmentation. Overall, 3:1 constructs with
higher DBM content achieved the greatest volume of bone augmentation exceeding 1:1 constructs
and empty implants by 3-fold and 5-fold, respectively. As such, we have established that a
synthetic, biodegradable hydrogel can function as a carrier for DBM, and that the volume of bone
augmentation achieved by the constructs correlated directly to DBM dose.
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1. Introduction
Bone augmentation can be broadly defined as the formation of bone beyond the existing
skeletal envelope at an orthotopic skeletal site. Bone augmentation may be attempted in the
vertical or lateral direction in a variety of geometries and may be required for functional
and/or aesthetic restoration. Inadequate bone volume may result from tooth extraction,
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disease, trauma, tumor resection, and other causes of deformities. Edentulous patients may
require bone augmentation for implant placement, and the disease causing tooth loss may
interfere with the effectiveness of bone augmentation procedures [1].
Clinical indications for augmentation surgery include alveolar ridge, sinus, or contour
deficits. Alveolar ridge augmentation treats deficits of the 3 classes in the bucco-lingual
and/or apico-coronal direction, which may involve shortage of width and/or height [1].
Sinus augmentation treats the atrophic posterior maxilla to enhance bone volume for implant
placement [2]. Contour deficits are characterized by insufficient bone volume or projection
at a skeletal site, which disrupts the expected facial contours [3]. Generally, autologous bone
is the best grafting material; however, synthetic or other natural materials provide an
alternative when autologous bone is unavailable, and off-the-shelf options greatly simplify
the procedure [4]. To study bone augmentation in a preclinical animal model, it was
essential to use an easily accessible region of compact bone with adequate space for surgery
and implantation. As such, we designed a rat model with augmentation of the parietal bone
in order to meet the above requirements, the parietal bone model having been established in
the literature with clear success [5–8].
Oftentimes, interventions of the above sort employ demineralized bone matrix (DBM), the
acid-extracted organic matrix of bone. DBM functions as an osteoinductive and
osteoconductive biomaterial delivering osteogenic growth factors in a bioresorbable form
[9]. Commercial DBM formulations often employ excipients, inactive substances primarily
added to enhance the handling properties [3]. Biopolymer excipients lack significant
tunability and suffer from irreproducibility compared to synthetic materials [10]. Using an
excipient neglects the potential of the carrier phase to augment the osteogenic activity of the
DBM. Some researchers have attempted to enhance DBM by adding growth factors
including BMP-2 [11], VEGF [12], and TGF-β1 [13]; however, considerable interest and
opportunity remains to explore the enhancement of any of these systems with the added
flexibility of a synthetic drug delivery system.
Synthetic hydrogels such as oligo(poly(ethylene glycol) fumarate) (OPF) have the potential
to enhance the osteogenic effect of DBM as injectable formulations for cell encapsulation
and controlled drug release [14]. To that end, we investigated whether OPF, in a simple and
unmodified form, could serve as a suitable delivery system for DBM. We hypothesized that,
in a rat model of bone augmentation, greater bone volume and height would be achieved by
OPF constructs with higher DBM content owing to the greater dose of osteogenic material
and to accelerated degradation.
2. Materials and Methods
2.1 Experimental design
The study was split into two parts. The first aimed at designing and testing the fabrication
process, elucidating the influence of DBM content and particle size on the physical
properties of the constructs, and testing the bioactivity of the DBM. The second part aimed
at investigating the constructs in the rat bone augmentation model and evaluating gross
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appearance, augmented bone volume, maximum height, and overall tissue appearance by
histology. The constructs formulated to complete the study design are listed in Table 1.
2.2 OPF synthesis
OPF was synthesized from poly(ethylene glycol) (PEG) (Sigma Aldrich, St. Louis, MO)
with nominal number average molecular weight of 3,350 Daltons (Da) as reported [14]. The
resulting OPF had number average molecular weight (Mn) 7500 ± 200 Da and weight
average molecular weight (Mw) 36,300 ± 600 Da as determined by gel permeation
chromatography using a Waters system with a Styragel HR 4E column and chloroform
solvent. The molecular weight was determined using a PEG standard curve.
2.3 DBM harvest and processing
DBM was harvested from the tibiae and femora of 12 week, Fischer 344, male rats based on
reported methods [15, 16] under the authorization of the Rice University Institutional
Animal Care and Use Committee. Briefly, bilateral tibiae and femora were harvested and
soft tissue was removed. The bone ends were removed and bone marrow was flushed with
PBS. Bones were crushed to yield bone fragments on the mm size scale. Fragments were
placed in 95% ethanol at 4°C for 16 h. The fragments were then moved to ethyl ether at 4°C
for 6 h. The bone fragments were filtered and dried. The fragments were further pulverized
in a mortar and pestle and sieved to achieve fractions in the range of 50–150 and 150–250
μm. The DBM particle fractions were demineralized in 0.6 M HCl at 4°C for 14 h then
filtered and dried. DBM particles were stored at −20°C.
2.4 Composite fabrication
In the present study, our delivery system was produced by mixing OPF hydrogel precursors
with DBM particles and cross-linking the OPF creating a hydrogel composite. Composites
were fabricated at a size matching the implants for the animal experiment (8 mm diameter x
1 mm height) using an established method [17] as follows. Dry components, OPF, PEG-
diacrylate (Glycosan BioSystems, Inc., Alameda, CA), and DBM, were combined and added
to PBS. Thermal radical initiators, ammonium persulfate and tetramethylethylenediamine
(Sigma Aldrich, St. Louis, MO), were added to initiate crosslinking and the mixture was
injected in a Teflon mold and incubated at 37°C for 8 min for crosslinking to proceed. After
8 min, the composite hydrogels were removed from the mold and cultured in vitro or
implanted in the rat. For the in vitro study, constructs were placed in 24 well plates in 1 ml
PBS or PBS supplemented with 400 ng/ml collagenase 1A (Sigma Aldrich, St. Louis, MO)
(Col PBS) to mimic the level of enzymatic digestion that would occur in vivo[18].
Composites were maintained at 37°C on a shaker table at 70 rpm with medium changes after
1 day and continuing twice weekly.
2.5 In vitro histology
Histology of in vitro samples was performed by embedding composite hydrogels in
Histoprep freezing media and making 10 μm frozen sections using a cryotome (Leica
1850CM UV). Sections were stained with Picrosirius Red to reveal the collagen matrix of
the DBM particles. Images were taken using a light microscope (Nikon Eclipse E600).
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2.6 Physical characterization
The composite hydrogels in the present study were characterized in terms of their
degradation, mass swelling, and compressive mechanical properties according to reported
methods [19]. Degradation or normalized mass was measured as the fraction of dry mass
remaining at day 1 and at 1, 3, and 5 weeks relative to the dry mass at day 0 (n=3 samples).
Mass swelling was measured as the ratio of wet weight to dry weight of the samples at each
time point at day 1 and at 1, 3, and 5 weeks (n=3). Compressive mechanical properties were
measured at 1, 3, and 5 weeks on a Thermomechanical Analyzer (TMA 2940, TA
Instruments, New Castle, DE) at a compression rate of 0.1 N/min where the compressive
modulus was determined as the initial slope of the stress-strain curve (n=3).
2.7 Osteogenesis assessment
The relative osteogenic activity of DBM was determined using the C2C12 cell line assay
(ATCC) [20]. C2C12 cells were expanded in high glucose DMEM medium with 10% fetal
bovine serum (BenchMark™ FBS, Gemini Bio-Products, West Sacramento, CA) for several
days. C2C12 cells were lifted with 0.25% trypsin and seeded at 50,000 cells per well in a 24
well culture plate and allowed to attach overnight (n=5). Medium was replaced with high
glucose DMEM with 1% FBS for the control or supplemented with 4 mg/ml DBM (based on
previous experiments that investigated this concentration[20]) with particle size of 50–150
μm for the test. Alkaline phosphatase (ALP) activity (nmoles p-Nitrophenol/h) was
determined and normalized to DNA (μg).
2.8 Animal surgeries
Animal surgeries were performed under the authorization and guidance of the Rice
University Institutional Animal Care and Use Committee and complete NIH requirements
were followed (NIH Publication #85-23 Rev. 1985). Surgery was performed on 24 animals
(12 week, Fischer 344, male rats) divided into 3 groups (n=8 per group). The groups
consisted of an empty Teflon ring and two composites with a DBM:OPF ratio of 1:1 or 3:1.
The surgical procedure and surgical setup were adapted from previous studies [5, 17].
General anesthesia and postoperative care were performed in a typical manner for surgeries
of this type [21]. The surgical procedure involved making a sagittal incision through the skin
over the parietal bone from approximately 2–3 mm anterior the coronal suture to 2–3 mm
posterior the lambdoid suture. A matching incision was made in the periosteum and the
tissue was carefully resected. A groove 0.3 mm in depth was drilled using an 8 mm trephine
bur in the parietal bone centered over the sagittal suture and just anterior to the lambdoid
suture. A Teflon ring of 1.3 mm height and 8 mm inner diameter was fit inside the groove.
After placing the implant inside the ring, the periosteum and skin were sutured in two layers
using running 5-0 and 4-0 Vicryl resorbable sutures, respectively. Animals were
administered systemic analgesia for a period of 36 h following surgery.
2.9 Tissue harvest
After 12 weeks implantation, animals were euthanized under isoflurane anesthesia by CO2
asphyxiation. Skulls were harvested using a cutting bur on a dental drill unit after blunt
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dissection of the overlying soft tissue leaving the periosteum intact. Specimens were fixed in
10% neutral buffered formation for 72 h and dehydrated in 70% ethanol.
2.10 Microcomputed tomography analysis
Microcomputed tomography (μCT) was performed on samples in 70% ethanol as described
previously [17]. Scans were performed at 40 kV and 250 mA on a SkyScan 1172 high-
resolution micro-CT (Bruker, Belgium). Bone volume in the region of interest was
determined with a thresholding range of 70–250. The region of interest was 8 mm diameter
x 1 mm height to match the implant dimensions. The position of the region of interest was
determined according to the uniform height of the Teflon ring and thickness of the parietal
bone between animals to ensure accurate positioning.
2.11 Histological analysis
Specimens were dehydrated in a series of ethanol and decalcified in 60 ml Formical 2000
(Decal Chemical Corp. Tallman, NY) with weekly refreshment for 3 weeks. Specimens
were soaked for 1 h in 15% sucrose, soaked overnight in 30% sucrose, and then embedded
in Histoprep freezing media and frozen at −60°C. Specimens were sectioned to 6 μm
thickness using a cryotome (Leica 1850CM UV). Sections were stained with hematoxylin
and eosin (H&E) and imaged on a Zeiss Axioimager Z2 light microscope.
2.12 Statistics
Data are reported as mean ± standard deviation. Statistical analysis was performed using
one-way ANOVA and Tukey’s HSD post-hoc test with a priori significance set to α=0.05.
3. Results
3.1 In vitro histology
Histological sections were made using 3:1 constructs with 50–150 μm DBM to demonstrate
the qualitative morphology of the DBM particles as well as their distribution in the
composites. A representative image is shown in Figure 1 although histology was performed
to confirm the particle morphology and homogeneous distribution in the other groups.
Morphology and distribution of the particles in 1:1 constructs is demonstrated in the in vivo
histology section. According to Figure 1 the size range is confirmed according to the
expected result of the sieving process, and particles appear as irregular polygons owing to
the nature of their processing.
3.2 Degradation
Degradation is reported in terms of normalized mass relative to the dry mass of each group
at day 0 as shown in Figure 2. Within each group the degradation increased as culture
progressed. An increase in DBM content correlated to faster degradation of hydrogels often
resulting in total degradation by 5 weeks. For DBM particle size of 50–150 μm, 3:1
constructs degraded in as little as 1 week whereas 1:1 constructs degraded within 5 weeks.
1:3 constructs degraded relatively little, still retaining half their original mass at 5 weeks.
For particle size of 150–250 μm, 3:1 constructs degraded in only 1 day, while 1:1 and 1:3
constructs did not degrade within 5 weeks. Culture in collagenase PBS did accelerate the
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degradation of the 1:1 constructs by 5 weeks, but no other effect of collagenase was
observed. Comparing between particle sizes, 3:1 constructs with 150–250 μm DBM
degraded most quickly whereas degradation was accelerated in 1:1 constructs with 50–150
μm DBM.
3.3 Mass swelling
Mass swelling is reported in terms of the wet weight to dry weight mass ratio at each time
point as shown in Figure 3. The data are not reported for any constructs that degraded prior
to the time point for swelling measurement. Within each group the swelling increased as
culture progressed. Of significance, 3:1 constructs with 50–150 μm DBM had a lower mass
swelling than other DBM contents, and for 150–250 μm DBM in collagenase, 1:1 constructs
had greater swelling than 1:3 constructs at 3 weeks.
3.4 Mechanical testing
A general measure of the mechanical properties of the constructs was determined by
measuring the compressive modulus of each construct. The compressive moduli are shown
in Figure 4. No data are reported for 3:1 constructs because they had degraded prior to the
earliest time point of study, and any other constructs that degraded prior to a predefined time
point could not be included in the analysis. Within each group the compressive modulus
decreased as culture progressed.
After culture time, DBM content exhibited the most significant effect on compressive
modulus with more DBM incorporation correlating to lesser mechanical properties.
Specifically, 1:3 constructs had greater moduli for 50–150 μm DBM at 1 week for both
media types and at 3 weeks for PBS and for 150–250 μm DBM at 1 week for collagenase
and 3 weeks for PBS. 50–150 μm DBM lowered the compressive moduli of 1:3 constructs in
PBS at 1 and 3 weeks and of 1:1 constructs in PBS at 1 week. Culture in collagenase
regularly reduced the compressive moduli of 1:3 constructs at 3 weeks for both particle
sizes. Collagenase also reduced the moduli of 1:3 constructs with 150–250 μm particles at 5
weeks and 1:1 constructs with 150–250 μm particles at 1 week.
3.5 Osteogenesis assessment
The relative baseline level of osteogenic activity of the DBM particles was determined by a
standard C2C12 cell culture assay. The results are shown graphically in Figure 5. After a 2-
day culture, the normalized ALP expression in the control group was unchanged whereas
supplementation with 4 mg/ml DBM particles (50–150 μm) increased the level of ALP
expression 4-fold (p<0.05).
3.6 Ex vivo gross appearance
At the time of specimen harvest after soft tissue dissection, gross images were taken to
record qualitatively the nature of the tissue in and around the Teflon ring and implant.
Representative images from each group are displayed in Figure 6. The Teflon ring is visible
through the periosteum in the transverse views. In Figure 6, the empty group (A) showed a
lack of significant tissue volume within the implant site, while the 1:1 (B) and 3:1 (C)
constructs demonstrated tissue and/or material filling up to the maximum height of the ring,
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which is visible in the images. The 1:1 group appeared to contain a significant amount of
OPF hydrogel as evidenced by the perimeter of the hydrogel disk indicated by the arrow in
(B).
3.7 Microcomputed tomography analysis
The volume of augmented bone was determined from μCT images, and the results are shown
in Figure 7B. The augmented volume refers to the absolute volume of bone that formed
beyond the existing skeletal envelope during the 12-week implant duration as defined above.
The empty, 1:1, and 3:1 groups achieved approximately 2, 3, and 10 mm3 of bone
formation, respectively. Accordingly, the 3:1 constructs achieved a 5-fold increase in
augmentation compared to the empty control group and a 3-fold increase compared to the
1:1 constructs (p<0.05).
The maximum height of augmented bone beyond the existing skeletal envelope was
determined from the μCT images, and the results are shown in Figure 7C. Regions of bone
augmentation facilitated by conduction along the Teflon ring were excluded from the
measurement to negate the influence of the augmentation model in this outcome. The
maximum height refers to the maximum height of bone augmentation achieved superior to
the native bone surface at 12 weeks within the region of interest defined earlier, which was
implemented in the augmented bone volume measurement. The empty, 1:1, and 3:1 groups
achieved approximately 0.19, 0.64, and 0.69 mm of maximum bone height, respectively.
Accordingly, the 3:1 and 1:1 constructs achieved at least a 3-fold increase in maximum bone
height compared to the empty control group (p<0.05).
3.8 In vivo histology
H&E staining was performed and representative sections are shown in Figure 8. In all
groups, bone formed predominantly from the parietal bone surface with location varying by
sample from exclusively around the sagittal suture to only on the periphery and anything in
between. Compact bone was formed in each group. Bone tended to conduct along the inside
edges of the Teflon ring in all groups. Greater volume of bone was consistently formed in
the 3:1 group. OPF was observed within in the 3:1 and 1:1 groups at 12 weeks. Greatest
bone volume directly correlated to greater soft tissue volume in the 3:1 implants.
3:1 constructs generated a large volume of both hard and soft tissue within the implant site.
DBM particles undergoing remodeling were observed in the augmented bone region with
unremodeled particles present in regions with only soft tissue present or where OPF was still
present at 12 weeks. DBM particles were homogeneously distributed at relatively high
density. Constructs appear to have retained much less of their original height in the center
part of the implant near the sagittal suture compared to the lateral portions.
1:1 constructs generated relatively little tissue within the implant site. DBM particles were
predominately unremodeled and remained encapsulated in OPF at 12 weeks. Particles were
homogenously distributed with relatively low density compared to 3:1 constructs. Constructs
appeared to maintain their original shape to a larger extent than 3:1 constructs.
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The empty group generated negligible tissue within the boundaries of the Teflon ring with
the periosteum regaining its placement immediately superior to the native bone. Bone
augmentation was localized to the periphery of the implant site with maximum bone height
formed adjacent to the Teflon ring.
4. Discussion
The present work investigated a new synthetic hydrogel system for the delivery of DBM.
Constructs were fabricated with DBM homogenously dispersed within the biodegradable
hydrogel, OPF. We first investigated the fabrication of constructs, the effect of DBM
content and particle size on construct physical properties, and the osteogenic activity of the
DBM. In the second part of the study, we investigated the ability of the hydrogel carrier to
deliver DBM for bone augmentation and answered the question of whether constructs with
higher DBM content would result in greater bone augmentation in volume and height by
μCT and histological appearance.
On construct fabrication, Picrosirius Red staining was implemented in the histological
analysis of in vitro samples to visualize DBM particles by their high collagen content. The
particles were homogeneously distributed throughout the hydrogel, which is important to the
consistency of the approach, and no problems were observed during the fabrication such as
agglomeration or precipitation of the particles. Further, the individual particle size appears
in the appropriate range from the sieving process, and the morphology is consistent with
typical DBM preparation [22]. Finally, construct fabrication proved to be a reproducible
process helping to ensure experimental accuracy.
The results from degradation, mass swelling, and mechanical testing together describe the
physical characteristics of the constructs and their dependence on fabrication parameters
including DBM content, DBM particle size, and media type. Because of the inherent
degradative property of OPF [23], and the interdependence of the various physical measures
[19], all constructs exhibited degradation, increased swelling, and decreased mechanical
properties over the course of study. With higher DBM content, constructs had accelerated
degradation, increased swelling, and lower mechanical properties, outcomes consistent with
the effect of increasing the content of a degradable gelatin microparticle porogen in these
hydrogels [19]. Thus the DBM content provides a means of tuning the physical properties of
these constructs as well as delivering the bioactive material at various dosages.
Focused upon the aim of investigating the effect of DBM content in vivo, the physical
characterization was performed to evaluate and understand the suitability of different
particle sizes for the physical performance of the constructs. DBM particle size had some
effect on the physical properties of the constructs with the exception of swelling. 50–150 μm
DBM tended to lower the mechanical properties of 1:3 and 1:1 constructs in PBS at early
time points and to result in faster degradation in 1:1 constructs by 5 weeks. The 50–150 μm
particles have greater surface area to volume ratio, which increases the interfacial area
between the hydrogel matrix and DBM particles. This change combined with the difference
in individual volume swelling of the two materials likely had a disruptive effect on the OPF
matrix that scaled with the size of the interface resulting in the observed effect on physical
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properties [19]. Collagenase culture was implemented along with PBS culture to more fully
understand the potential effects of DBM content and particle size in an environment more
similar to that of conditions experienced in vivo [24]. The effect of collagenase culture was
of varying importance to the different physical measures in the present study. With regard to
degradation and mass swelling the effect of collagenase was limited; however collagenase
culture regularly lowered the mechanical properties of the constructs by 3 weeks. To explain
this effect, individual DBM particles composed of collagen undergo bulk degradation in the
presence of the enzyme. At an intermediate state, reduced crosslinking density allows
greater volume swelling of the DBM, which mechanically disrupts the surrounding OPF
matrix [24]. This effect reduces the mechanical properties of the construct without greatly
influencing degradation or mass swelling thus showing the potential effect of in vivo culture
conditions on construct mechanical properties.
In summary, we established a proof of concept for using OPF as a delivery system for DBM,
and DBM content and particle size had important effects on the various physical properties
investigated. The 50–150 μm particle size range presented the most favorable option for
further in vitro and in vivo testing based on accelerated degradation of the 1:1 constructs,
better handling properties of the 3:1 constructs, and increased surface area for tissue contact
and remodeling. Furthermore, 1:1 and 3:1 constructs were investigated in vivo due to their
accelerated degradation.
An in vitro assay was utilized in this work to confirm the osteogenic activity of the rat-
derived DBM. The induction of C2C12 cells to upregulate their production of ALP is an
established method of determining the relative osteogenic potential of various materials [20,
25, 26], and the method has been validated against an in vivo osteoinductivity model [20].
The DBM particles evaluated in the present work maintained high levels of osteogenic
bioactivity as evidenced by the upregulation of ALP 4-fold compared to the control culture.
Considering the use of established methods for its preparation and its osteogenic activity, the
DBM utilized in the present work was expected to display bioactivity in vivo.
The present work implemented a new surgical setup for bone augmentation in the rat shown
schematically in Figure 7A. Our model was designed in large part based on lessons learned
from two previous models in the rat. In the first, investigators implanted two anterior/
posterior implants (6 mm diameter, 2 mm height) per rat within groove-immobilized Teflon
rings, and the authors used the model for the study of porous CPC [5]. In the second study,
our laboratory implanted two left/right implants (6 mm diameter, 2 mm height) per rat
within screw-immobilized polypropylene cassettes [17]. Though less influential to our
design, others have used subperiosteal pockets [7, 27–30], non-immobilized rings [6, 31],
and groove [8, 32] or screw immobilization [33–35]. Our new model has the advantage of
matching the dimensions of the rat critical-sized calvarial defect (8 mm diameter) [36]
allowing scaffolds to be tested directly for bone augmentation without repeating in vitro
characterization. Our model also incorporates advantages of previous models such as rigid
immobilization to prevent micromotion and use of the Teflon ring to prevent soft tissue
compression of the implant.
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Recognizing the potential hindrance to bone augmentation of having degradation proceed
more slowly than tissue ingrowth in hydrogel constructs [17], designing constructs that
completely degraded in vitro on an abbreviated timescale would be promising to the
application of these constructs in vivo. Even in vitro degradation periods as brief as 1 week
like we observed in some groups would be expected to scale to several weeks in vivo
providing adequate support for bone induction based on the correlation of in vitro and in
vivo degradation rates observed previously in composite hydrogels [37]. This outcome was
observed whereby 3:1 constructs degraded almost entirely within 12 weeks in vivo
evidenced by histology sectioning. Thus, the more rapid degradation proved to suit the
augmentation strategy by providing more void space for bone augmentation compared to the
more slowly degrading 1:1 constructs, which remained largely intact at study completion.
This result gleaned from histology aligned with observations of the gross appearance of 1:1
constructs as shown in Figure 6.
As to the animal model implemented in the present study, the ex vivo images show excellent
gross healing of the periosteum, complete degradation of the subcutaneous sutures,
reproducible and immobile placement of the Teflon ring, and lack of noticeable deformation
of the ring with time. The most definitive single measure to the outcome of a scaffold-based
approach to bone augmentation is the total volume of augmented bone in the implant site.
Traditionally, augmented bone volume has been determined by either histomorphometry or
μCT. Histomorphometry has the inherent drawback of providing a segmented view of the
region of interest based on the spacing of sections on which the calculation is performed
followed by averaging and scaling the result [31, 32]. μCT on the other hand, provides a
complete view of the region of interest [8, 17, 38]. As such, we employed μCT imaging in
the present investigation to quantify new bone formation and histology for qualitative
information about the new tissue formation. The DBM content of the constructs had a
significant impact on the volume of bone augmented. 3:1 constructs produced more than 3-
fold greater bone volume compared to the 1:1 constructs and 5-fold greater bone compared
to the empty controls. Coincidentally, 3:1 constructs contained a 3-fold greater concentration
of DBM compared to 1:1 constructs, and ectopic bone volume has been shown to vary
linearly with DBM dose [39]. While the incorporation of DBM likely acts dose-dependently
based on its osteogenic bioactivity [20], the changes in construct physical properties have
potential to significantly affect the outcome by way of accelerated degradation of the OPF
hydrogels. In previous studies, when OPF hydrogels showed delayed degradation in vivo,
tissue ingrowth was hindered [17, 40]. According to our histology, the 1:1 constructs
retained a high proportion of OPF within the implant site at 12 weeks, which likely inhibited
tissue ingrowth and prevented significant augmentation from occurring. The 3:1 constructs,
on the other hand, are mostly void of OPF at 12 weeks, indicating accelerated degradation,
which would have enabled tissue ingrowth to occur more freely and result in greater
augmentation.
While the results of total augmented bone volume varied due to DBM content, the maximum
height of augmented bone was similar between 3:1 and 1:1 constructs, both exceeding the
empty control by at least 3-fold. From μCT, 3:1 constructs often displayed robust
augmentation with interconnected bone spanning from the native surface to the maximum
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height. However, 1:1 constructs often resulted in a somewhat more disconnected bone
structure whereby the maximum height was achieved by a rogue bone nucleation site. 1:1
constructs then show potential to perform well in terms of augmented bone volume but may
require a longer time to allow greater OPF degradation in order to match the performance of
the 3:1 constructs.
Finally, the histology staining was able to extend, explain, and reinforce the many notable
outcomes already described. Compression of augmentation implants due to tension in the
overlying soft tissue has been shown to reduce total bone augmentation [6]. The 3:1
implants showed height reduction in their center by histology; however, the effect did not
reduce the volume of bone augmented in that region compared to the periphery showing that
the model used was capable of projecting the potential of the treatment in the absence of
compressive forces.
To our knowledge, the present study represents the first application of a synthetic hydrogel
for the delivery of DBM for bone augmentation. Besides functioning as an excellent inert
carrier, OPF can be utilized for encapsulation of mesenchymal stem cells [41], growth factor
[42] or gene delivery [43], and incorporation of cell binding moieties [44], or other
osteoconductive domains [45, 46]. Thus, the OPF hydrogel presents a platform technology
for future development of the carrier phase to augment the osteogenic bioactivity of DBM.
5. Conclusion
The present work evaluated the bone augmenting effect of DBM delivered via OPF
synthetic hydrogels. Rat-derived DBM demonstrated osteogenic activity and constructs
could be fabricated with homogeneous particle dispersion. The physical properties of the
constructs were evaluated, and we observed degradation, increased mass swelling, and
decreased mechanical properties with culture time. Higher content of DBM accelerated
those changes, and variation due to particle size was dependent on the content as well. The
effect of DBM content was investigated in a vertical augmentation model in the rat, and we
observed a dose dependent effect of DBM on the volume of bone augmentation but not on
maximum height. The results were confirmed and further explained by histological staining.
Altogether an innovative DBM delivery system is provided.
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Figure 1.
Picrosirius Red stained 10 μm thin section of a representative 50–150 μm, 3:1 DBM:OPF
construct showing red staining for collagen (original magnification 10x).
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Figure 2.
Degradation of 1:3, 1:1, and 3:1 DBM:OPF constructs in PBS and Col PBS (400 ng/ml
collagenase 1A) with 50–150 μm DBM particle size in (A) and 150–250 μm in (B). Error
bars indicate + 1 standard deviation from the mean (n=3). Significant differences at each
time point are indicated by * for DBM content, # for DBM particle size, and + for
collagenase culture (p<0.05).
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Figure 3.
Mass swelling of 1:3, 1:1, and 3:1 DBM:OPF constructs in PBS and Col PBS (400 ng/ml
collagenase 1A) with 50–150 μm DBM particle size in (A) and 150–250 μm in (B). Error
bars indicate + 1 standard deviation from the mean (n=3). Significant differences at each
time point are indicated by * for DBM content (p<0.05).
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Figure 4.
Compressive moduli of 1:3 and 1:1 DBM:OPF constructs in PBS and Col PBS (400 ng/ml
collagenase 1A) with 50–150 μm DBM particle size in (A) and 150–250 μm in (B). Error
bars indicate ± 1 standard deviation from the mean (n=3). Significant differences at each
time point are indicated by * for DBM content, # for DBM particle size, and + for
collagenase culture (p<0.05).
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Figure 5.
Normalized ALP levels for C2C12 cells cultured in general media (control) or general media
supplemented with 4 mg/ml 50–150 μm DBM (DBM) for 2 days. Alkaline phosphatase
(ALP) activity (nmoles p-Nitrophenol/h) was determined and normalized to DNA (μg).
Error bars indicate + 1 standard deviation from the mean (n=5). Bars connected with
horizontal lines with the * symbol are significantly different (p<0.05).
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Figure 6.
Gross images taken at specimen harvest after dissection of soft tissue showing representative
samples from the empty (A), 1:1 (B), and 3:1 (C) groups. Images show the transverse plane
viewed from directly above. The Teflon ring is visible in white. The black arrow indicates
the circular edge of an intact disc shaped construct.
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Figure 7.
Coronal and transverse schematic views of the surgical setup for the augmentation
procedure (A), augmented bone volume in the region of interest (B), maximum height of
new bone in the region of interest measured from the native bone surface (C), and
representative raw μCT images showing mineralized tissue in the coronal plane (D). Error
bars indicate + 1 standard deviation from the mean (n=8). Bars connected with horizontal
lines with the * symbol are significantly different (p<0.05). The red dashed line indicates the
region of interest in (A). The groove drilled for ring placement is visible at the lateral edges
of each image in (D). The scale bar in (D) represents 1 mm.
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Figure 8.
Representative coronal H&E stained histological sections from the empty (A), 1:1 (B), and
3:1 (C) groups (original magnification 10x). The scale bar indicates 0.5 mm. Augmented
bone is indicated by the *, DBM particles by arrows, and the OPF hydrogel is labeled “H”.
Kinard et al. Page 22
Acta Biomater. Author manuscript; available in PMC 2015 November 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Kinard et al. Page 23
Table 1
IN VITRO
DBM:OPFa Particle size (μm) Media
1:3 50–150/150–250 PBS/Col PBSb
1:1 50–150/150–250 PBS/Col PBS
3:1 50–150/150–250 PBS
IN VIVO
DBM:OPF Particle size (μm)
1:1 1:1 50–150
3:1 3:1 50–150
Empty N/A N/A
a
DBM:OPF refers to the ratio of the components on a dry weight basis
bCol PBS refers to PBS supplemented with 400 ng/ml collagenase 1A
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